Foundation Medicine and its collaborators recently announced results from a prostate cancer study evaluating the landscape of genomic alterations identified by liquid biopsy in over 3,000 patients and assessing concordance of liquid and tissue biopsy in over 800 patients. The study demonstrated high concordance between targetable alterations identified using circulating tumor DNA (ctDNA) and tissue-based comprehensive genomic profiling (CGP) in patients with metastatic castration-resistant prostate cancer (mCRPC). It also found that, in many patients, liquid biopsy detects more acquired resistance mechanisms than a tissue biopsy. 

Biographies:

Geoffrey Oxnard, MD, Vice President and Global Medical Lead at Foundation Medicine, Boston, Massachusetts